Brief: Pharmacyte Biotech Launches Malignant Ascites Program With Preclinical Study
30/11/2021 06:07
Nov 30 (Reuters) - PharmaCyte Biotech Inc PMCB.O :
* PHARMACYTE BIOTECH LAUNCHES MALIGNANT ASCITES PROGRAM WITH
COMMENCEMENT OF PIVOTAL PRECLINICAL STUDY
Source text for Eikon: ID:nBw7GDRZva
Further company coverage: PMCB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmacyte Biotech
See all newsBrief: Pharmacyte Biotech Inc - Increases Stake In Tnf Pharmaceuticals By $3 Million
Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer